Given the promising treatment results with checkpoint inhibitors in cervical carcinomas [14–16] and the positive correlation of Trop2 positivity with immunohistochemical PD-L1 expression and the presence of a high rate of tumor infiltrating lymphocytes (TIL) [29], a combination of Trop2-targeted therapy with immuncheckpoint inhibition is suggested. The gene discussed is TACSTD2; the disease is neoplasm.